Physician profile
Teri A Lower
NPI 1083659643
$7,145.32
in general payments reported to CMS, 2019-2025
26 companies · $2,135 in 2025
The $2,135 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $157 · 2021: $35.54 · 2022: $339 · 2023: $1,388 · 2024: $1,922 · 2025: $2,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,179 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,178.77 |
| Education | $265.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,278.75 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Csl Behring | $890.00 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $886.92 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $648.97 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $566.89 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $469.03 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Novartis Pharmaceuticals Corporation | $422.66 | 2019-2025 | |
| Genzyme Corporation | $326.84 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $269.10 | 2023-2025 | Orladeyo |
| Amgen INC. | $267.69 | 2022-2025 | Tezspire |
| Shire North American Group INC | $144.86 | 2019 | |
| Grifols USA, LLC | $136.05 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Pharming Healthcare, INC. | $124.63 | 2024-2025 | Ruconest |
| Hospira, INC. | $108.02 | 2024-2025 | |
| Leo Pharma INC. | $98.23 | 2022-2024 | Adbry |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88.47 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $67.99 | 2024 | |
| Kaleo, INC. | $59.31 | 2019 | |
| Bio Products Laboratory USA, INC. | $55.59 | 2019-2023 | Gammaplex, Coagadex |
| Lilly USA, LLC | $48.62 | 2024-2025 | Ebglyss |
| Optinose US, INC. | $44.39 | 2020-2024 | |
| Mylan Specialty L.P. | $39.90 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.72 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $31.16 | 2025 | Neffy |
| Paratek Pharmaceuticals, INC. | $17.34 | 2025 | Xhance |
| Sunovion Pharmaceuticals INC. | $14.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Lower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.